BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20723307)

  • 1. [Determination of leukemia stem cells in childhood acute myeloid leukemia and its clinical significance].
    Wang D; Tang YM; Xu XJ; Shen HQ; Qian BQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):952-8. PubMed ID: 20723307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
    Lv JT; Yang ZG; Guang YH; Lin ZS; Xiao XX; Liu D; Shi M; Wang WS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
    Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of 5 genes in CD7 positive acute myeloid leukemia stem/progenitor cells from bone marrow].
    Wu HH; Cao H; Wang YZ; Wang DX; Lin HR; Qin YZ; Chang Y; Hao L; Li LD; Li JL; Ruan GR; Huang XJ; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):298-303. PubMed ID: 19379555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34
    Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia.
    Hwang K; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
    Ann Hematol; 2012 Oct; 91(10):1541-6. PubMed ID: 22669506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
    Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
    Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.